key Try Dr. Mendelssohn's poll: INITIAL CHOICE OF ESRD THERAPY. This poll, which has no right or wrong answers, is meant to query renal health providers about their approach to patients approaching dialysis, especially in terms of which potential options for therapy are presented to such patients.
Note: Use Internet Explorer only; feedback section does not work with some other browsers.


Foley  

Sica  

Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease
Robert N. Foley, MD, and Domenic A. Sica, MD. (ASN Renal Week, 2006). Foley: How are classic and novel risk factors related to outcome in CKD patients as well as in dialysis patients? What can we learn from Framingham data? From NHANES? Which of the classical risk factors works in the opposite direction when GFR is low? To what extent have patients with mild-moderate CKD been excluded from the major cardiovascular trials? What can we learn from analysis of these subsets? How do the observational data differ from randomized, controlled trials?
Sica: How are the pathogenses of CKD and CVD (cardiovascular disease) related? Where do both impact the RAS (renin-angiotensin system)? How does ACE inhibition affect different parts of the cardiovascular system? What conclusions can we draw from AASK? How can we rationally choose drugs from different classes to treat hypertension? How should different calcium-blockers and ACE inhibitors be used in CKD? How do ACE inhibitors and ARBs compare? (ASN Renal Week Official Symposium, 2006).
(more...)



Haley

Implementation of the RPA CKD Toolkit and its Potential Impact on P4R and P4P
(RPA 2006, General Session 1)
What lessons did we learn from the Advanced CKD Guideline Implementation Project? Unlike ESRD, resources for CKD are not optimally distributed. Substantial numbers of pre-ESRD patients are managed by PCPs, and management does not conform to guidelines. (more...)

Updated: July 03, 2008 (J03)
J03 Secondary analysis of CHOIR data suggests that high EPO doses, rather than high Hb per se, associated with mortality.
J19 Is fluoride in drinking water safe for patients with CKD?
J10 Large Australian RCT specifically shows that lowering HbA1C in diabetics to a 6.5% target protects the kidney.
J05 NEJM: Aliskiren plus losartan lowers proteinuria in diabetics.
M12 Should the NKF KDOQI staging system for CKD be modified?
M07 JASN: Calcitriol associated with a lower mortality in pre-ESRD patients.
M05 ASN Renal Week abstract archives 2003-2006 now available on-line in .pdf format.
A09 NEJM: ACEI = ARB, and ACEI + ARB no better than either ACEI or ARB, in high risk patients with diabetes or vascular disease.
M20 JASN Express: Remission clinic targetting proteinuria with multidrug therapy markedly slows rate of CKD progression.
M06 7th Annual Prevention in Renal Disease Conference, Toronto, Sept. 19-20, 2008.
M01 Screening test for CKD (SCORED) developed by Cornell and UNC Chapel Hill outperforms NKF KEEP approach.
F26 Diazyme introduces new assay for cystatin C.
F21 Study suggests that Medicare part D patients use more cardioprotective drugs after MI and live longer.
F13 University of Groningen study (PREVEND) emphasizes utility of treating hypertension in proteinuric patients.
J24 Researchers cast doubt on UK's universal screening program for CKD.
Industry Advances Emphasis
archive
Secondary Hypertension, including Chronic Kidney Disease ASN Board Review 2006
Pathogenesis and Management of Cardiovascular Disease (CVD) in Chronic Kidney Disease ASN Renal Week 2006
Emerging New Agents in Diabetic Kidney Disease (Lewis) ASN 2005 Renal Week
CKD Management: What Can We Learn from South African and Australasian Efforts? (Katz) RRI 2006, Part 3 (handouts)
Implementation of the RPA CKD Toolkit and its Potential Impact on P4R and P4P (Haley) RPA 2006, General Session 1
CKD Outcomes (Somermeyer) RPA 2006, General Session 4
Anemia Management in CKD: Improving Iron Management (Reed, Copeland) ANNA 2006
Medical Crossfire: An Expert Panel Debates Key Clinical Issues in Mineral Metabolism and Mortality in CKD (Coyne, Moe, Martin) ASN Renal Week 2005
The Pathophysiology of Progressive Renal Disease and Hypertension: Importance of Gender and Ethnicity (August, Maric, Thomas, Lewis) ASN Renal Week 2005 (audiofiles)
Evidence for a New Treatment Paradigm in the Management of Secondary Hyperparathyroidism in CKD Stages 3 and 4 (Andress, Coyne) ASN Renal Week 2005 (audiofiles)
Redefining Outcomes in CKD (London, Block) ASN Renal Week 2005 (audiofiles)
Developing Therapeutics for Progressive Renal Disease (Martin, Mauer, Klein, Throckmorton, Hostetter, Kopp) ASN Renal Week 2005 (audiofiles)
RPA’s Advanced CKD Patient Management Tool Kit: How to improve care (Goldman) RPA 2005
Information Systems to Monitor CKD Patient Management (Fadem) RPA 2005
Complications of Anemia and the CKD Patient (Petroff) ANNA 2005
Caring Through the End: Palliative Care Along the Continuum of CKD. (Various) MARC 2004

Should patients with venous thromboembolism be screened for thrombophilia? Am J Med (Jun 2008)
Role of remission clinics in the longitudinal treatment of CKD J Am Soc Nephrol (Jun 2008)
Adynamic bone in patients with chronic kidney disease Kidney Int (Jun 2008)
Lipid abnormalities and cardiovascular risk in renal disease J Am Soc Nephrol (Jun 2008)
Urinalysis: core curriculum 2008 Am J Kidney Dis (Jun 2008)
Efficacy and safety of fondaparinux and enoxaparin for acute coronary syndromes in CKD Am J Kidney Dis (May 2008)
Staging of chronic kidney disease: time for a course correction J Am Soc Nephrol (May 2008)
Nephrogenic systemic fibrosis: early recognition and treatment Semin Dial (Apr 2008)
Atherosclerotic renal artery stenosis: overtreated but underrated? J Am Soc Nephrol (Apr 2008)
Targeting proteinuria as a valid surrogate for individualized kidney protective therapy Am J Kidney Dis (May 2008)
The utility of the transtubular potassium gradient in the evaluation of hyperkalemia J Am Soc Nephrol (Mar 2008)
The Janus faces of allopurinol -- allopurinol hypersensitivity syndrome Am J Med (Mar 2008)
Systematic Review: Randomized, controlled trials of nonsurgical treatments for urinary incontinence in women Ann Intern Med (Mar 2008)
Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease Am J Nephrol (Mar 2008)
National Institutes of Health State-of-the-Science Conference Statement: Prevention of fecal and urinary incontinence in adults Ann Intern Med (Mar 2008)
Protein restriction and body composition in renal disease J Ren Nutr (Mar 2008)
Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease Am J Nephrol (Mar 2008)
Association between obesity and kidney disease: A systematic review and meta-analysis Kidney Int (Jan 2008)
Dermatological disease in patients with CKD Am J Kidney Dis (Feb 2008)
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease Nephrol Dial Transplant (Feb 2008)
The impact of population-based identification of chronic kidney disease using estimated glomerular filtration rate (eGFR) reporting Nephrol Dial Transplant (Feb 2008)
Mechanisms of vascular calcification in chronic kidney disease J Am Soc Nephrol (Feb 2008)
Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study Brit Med J (Feb 2008)
Low birth weight is associated with chronic kidney disease only in men Kidney Int (Feb 2008)
Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes Nephrol Dial Transplant (Feb 2008)
Beta-blockade in chronic dialysis patients Semin Dial (Feb 2008)
Poor correlation between coronary artery calcification and obstructive coronary artery disease in an end-stage renal disease patient Hemodial Int (Jan 2008)
Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease Ann Intern Med (Jan 2008)
Early Start Peritoneal Dialysis Adv Chronic Kidney Dis (Jul 07)
Intensive versus moderate blood-pressure control in normotensive patients with type 2 diabetes (Briggs J) NCPN Jun 07
The ESRD uninsured matter (Williams) Adv CKD (02-2007)
KDOQI Clinical Practice Guidelines and CPRs (2006 update) for Treatment of Diabetes and CKD AJKD (Feb 07)
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. (A. Levin et al) Kidney Int 01-07
Core Curriculum: Chronic Kidney Disease (Lederer, Ouseph) Am-J-Kidney-Dis 01-2007
Aldosterone and Cardiovascular Disease. Smoke and Fire (Calhoun). Circulation 12-06
Obesity: Growing Impact on CKD (McGill, Furth, Kaskel) Adv Chronic Kidney Dis 10-06
Management of dyslipidemias in patients with diabetes and chronic kidney disease (Molitch). CJASN 09-06
K/DOQI CKD GUIDELINES
When to initiate dialysis (1-2) CKD-Diabetes, 2006
GFR CALCULATORS
MDRD GFR per 1.73 M2
HDCN Topic Pages (KEY)
Pre-ESRD care
Dialysis outcomes
Quality Assurance
Progression of CKD
Etiology of CKD
OTHER GUIDELINES
Healthy People 2010 CKD
VA Guidelines
Canadian: Elevated Scr
NIDDK CKD Info
STILL MORE LINKS
U.S. NKF

David Mendelssohn, M.D.
Head, Division of Nephrology; Medical Director of Dialysis, Humber River Regional Hospital; Associate Professor of Medicine University of Toronto, CANADA.